GSK Launches Phase III Trial of Combined COVID-19 mRNA and RSV Protein Vaccine Regimen
GSK
Pharmaceutical R&D Manufacturer
April 1, 2024August 8,GlaxoSmithKline PLC.Phase III Clinical Trial of RSV Recombinant Protein Vaccine + COVID-19 mRNA Vaccine Combined Immunization Registered on Clinicaltrials.gov.
This Phase III clinical trial plans to enroll 850 healthy subjects, with preliminary completion expected in October 2024 and final completion in May 2025.
For the combined immunization group, subjects received one dose of RSV protein vaccine and one dose of COVID-19 mRNA vaccine.
The study endpoints were RSV neutralizing antibody titers and COVID-19 neutralizing antibody titers.
About GSK
GSK is one of the largest multinational pharmaceutical companies in China, with a total investment of over 500 million U.S. dollars, more than 5,000 local employees, one global full-function R&D center, and six production bases in China. With three major businesses, GSK helps improve the health of millions of people worldwide by researching, developing, and manufacturing innovative medicines, vaccines, and consumer healthcare products. GSK aims to become one of the most innovative, high-performing, and trusted global healthcare companies.